📣 Zent2U is happy to announce that we successfully completed the development of a generic version of Entresto® 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg film coated tablets (Novartis®), based on successful results of series of bioequivalence studies.
🌍 Having all necessary studies completed, the respective eCTD dossier has been compiled for registration submission with EU regulatory authorities. We have successfully developed a proprietary technical solution, that will allow us and our customers to bring an Entresto generic to the market at the earliest possible date.
👨👩👧👦 Sacubitril in combination with Valsartan is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction, in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction.
🤝 Having our dossier in place allows our potential partners to enrich their portfolio of cardiovascular treatment with a new generic product to offer efficient and cost-effective treatment to their patients as well as launch the product in the first generic wave.
📧 Partner up now and connect with our team today!
thomas.koene@zentiva.com - Thomas Koene - Head of Zent2U
tomas.pilarcik@zentiva.com – Tomas Pilarcik – Head of B2B Europe
rahul.padhye@zentiva.com – Rahul Padhye – Head of B2B International
nina.fuentes@zentiva.com – Nina Fuentes de Tienda – Key Account Manager B2B Europe
yuliyana.manolova@zentiva.com – Yuliyana Manolova – Head of Distribution and Clinical Trials
cardiovascular outlicensing B2B Zent2U Zentiva
